Unum Therapeutics transfers BOXR cell-based therapy to Sotio

By The Science Advisory Board staff writers

September 1, 2020 -- Unum Therapeutics has sold its Bolt-on Chimeric Receptor (BOXR) cell-based therapy technology to immuno-oncology firm Sotio.

Sotio will pay $8.1 million upfront for the BOXR technology and assume development of Unum's lead candidate, BOXR1030. Unum will also be eligible for future milestone payments of up to $3.4 million. The deal closed on August 28.

As part of the agreement, Sotio will assume responsibility for a portion of Unum's facilities in Cambridge, MA, to advance the BOXR programs. In addition, certain Unum staff associated with the BOXR programs will transition to Sotio.

Meanwhile, Unum said it has retained its antibody-coupled T cell receptor (ACTR) technology and continues to explore strategic opportunities for its technology and assets. It will also retain certain staff and space in its Cambridge facilities as it refocuses on the development of small-molecule precision kinase inhibitors, including its PLX9486 lead program. Unum said it will reinvest the net proceeds of the BOXR sale into the development of PLX9486.

In other company news, Unum has appointed Peter Harwin as its board chair. Harwin is co-founder and managing member of Fairmount Funds Management, and also played an integral role in Unum's recent acquisition of Kiq, according to the firm.


Copyright © 2020 scienceboard.net
 

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:



Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Email Preferences



Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.